InvestorsHub Logo
Followers 69
Posts 6498
Boards Moderated 0
Alias Born 02/10/2010

Re: Steve43 post# 218794

Wednesday, 03/11/2020 10:09:26 AM

Wednesday, March 11, 2020 10:09:26 AM

Post# of 330188
What a Load of Misinformation/Hogwash

CVS was 200 a Store Product Trial not a consummated business deal. AW did not like the percentage of revenue BIEL got vs Protex the sleeve maker. Should he have gone with it anyway for the exposure, absolutely. AW is no longer making decisions at BIEL.

Dr. Scholl's was never a consummated business deal. Scholl's wanted a Licensing Deal but AW did not want to hand over the ActiPatch IP. Should he have given them the Licensing Deal, probably. AW is no longer making decisions at BIEL.

RecoveryRx, some speculated that RecoveryRx would be more profitable than ActiPatch. IMO this was never the case. Unless one has the resources of a J&J or Pfizer, to shape the sentiments of the medical community, a OTC product is always going to be a smoother path to revenue than a prescription product. RecoveryRx will find its Market and provide BIEL with revenue.

KW proved that she did not agree with AW's business decisions when she reached out to Dr. Scholl's, CVS, and KT-Tape to try and revive the deals that AW turned down.

<<<<<<< IMO, we won't see anything till all 3 deals are finalized >>>>>>

This opinion is incorrect. Dr. Scholl's and DJ Orthopedics are major established names in their Markets. Announcement of each signed Deal will increase BIEL's SP.